for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency

March 23 (Reuters) - Celsion Corp:

* CELSION’S GEN-1 IMMUNOTHERAPY RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY

* CELSION CORP - GEN-1 PREVIOUSLY RECEIVED ORPHAN DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION

* CELSION CORP - GEN-1 IS CURRENTLY BEING EVALUATED IN A PHASE I/II CLINICAL TRIAL FOR TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH STAGE III AND IV OVARIAN CANCER. Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up